U.S. Markets closed

Arena Pharmaceuticals, Inc. (ARNA)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
24.35+0.01 (+0.04%)
At close: 4:00PM EDT

24.24 -0.11 (-0.45%)
After hours: 7:20PM EDT

People also watch
VVUSOREXARIAKERXAMRN

Arena Pharmaceuticals, Inc.

6154 Nancy Ridge Drive
San Diego, CA 92121
United States
858-453-7200
http://www.arenapharm.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees106

Key Executives

NameTitlePayExercisedAge
Mr. Amit D. MunshiPres, CEO & Director644.43kN/A49
Mr. Kevin R. LindChief Financial Officer and Exec. VP342.33kN/A41
Mr. Steven W. Spector J.D.Exec. VP, Gen. Counsel and Sec.638.3kN/A52
Mr. Vincent E. AurentzChief Bus. Officer and Exec. VP274.24kN/A49
Ms. Cate ScanlonVP of Global HRN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel small molecule drugs for various therapeutic areas in the United States and Switzerland. The company’s proprietary investigational clinical programs include etrasimod (APD334), which is in Phase IIb evaluation for ulcerative colitis, as well as is in Phase IIa evaluation for dermatologic extraintestinal manifestations in inflammatory bowel disease, pyoderma gangrenosum, and primary biliary cholangitis; ralinepag that is in Phase IIb evaluation to treat pulmonary arterial hypertension; and APD371, which is in Phase IIa evaluation for the treatment of pain associated with Crohn's disease. It has collaboration agreements with Eisai Inc.; Eisai Co., Ltd.; Axovant Sciences Ltd.; and Boehringer Ingelheim International GmbH. Arena Pharmaceuticals, Inc. was founded in 1997 and is based in San Diego, California.

Corporate Governance

Arena Pharmaceuticals, Inc.’s ISS Governance QualityScore as of July 1, 2017 is 2. The pillar scores are Audit: 1; Board: 1; Shareholder Rights: 3; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.